S
Sarah L. Gulliford
Researcher at University College London Hospitals NHS Foundation Trust
Publications - 89
Citations - 2312
Sarah L. Gulliford is an academic researcher from University College London Hospitals NHS Foundation Trust. The author has contributed to research in topics: Prostate cancer & Radiation therapy. The author has an hindex of 24, co-authored 84 publications receiving 1915 citations. Previous affiliations of Sarah L. Gulliford include University College London & The Royal Marsden NHS Foundation Trust.
Papers
More filters
Journal ArticleDOI
Independent validation of genes and polymorphisms reported to be associated with radiation toxicity: a prospective analysis study.
Gillian C. Barnett,Gillian C. Barnett,Charlotte E. Coles,Rebecca Elliott,Caroline Baynes,Craig Luccarini,Don M. Conroy,Jennifer S. Wilkinson,Jonathan Tyrer,Vivek Misra,Radka Platte,Sarah L. Gulliford,Matthew R. Sydes,Emma Hall,Søren M. Bentzen,David P. Dearnaley,Neil G. Burnet,Paul D.P. Pharoah,Alison M. Dunning,Catharine M L West +19 more
TL;DR: This prospective study validated reported associations between genotype and radiation toxicity in a large independent dataset and did not replicate previously reported late toxicity associations, suggesting that the hypothesis that published SNPs individually exert a clinically relevant effect is essentially excluded.
Journal ArticleDOI
Dose―volume constraints to reduce rectal side effects from prostate radiotherapy: evidence from mrc rt01 trial isrctn 47772397
Sarah L. Gulliford,K. Foo,Rachel C Morgan,Edwin Aird,A. Margaret Bidmead,Helen Critchley,Philip M. Evans,Stefano Gianolini,W. Philip M. Mayles,A. Rollo Moore,Beatriz Sánchez-Nieto,Mike Partridge,Matthew R. Sydes,Steve Webb,David P. Dearnaley +14 more
TL;DR: Considering the entire dose distribution to the rectum by applying dose-volume constraints such as those tested here in the present will reduce the incidence of late rectal toxicity.
Journal ArticleDOI
A genome wide association study (GWAS) providing evidence of an association between common genetic variants and late radiotherapy toxicity.
Gillian C. Barnett,Gillian C. Barnett,Deborah J. Thompson,Laura Fachal,Sarah L. Kerns,Christopher J. Talbot,Rebecca Elliott,Leila Dorling,Charlotte E. Coles,David P. Dearnaley,Barry S. Rosenstein,Ana Vega,Paul Symonds,John Yarnold,Caroline Baynes,Kyriaki Michailidou,Joe Dennis,Jonathan Tyrer,Jennifer S. Wilkinson,Antonio Gómez-Caamaño,George A. Tanteles,Radka Platte,Rebecca Mayes,Don M. Conroy,Mel Maranian,Craig Luccarini,Sarah L. Gulliford,Matthew R. Sydes,Emma Hall,Joanne S Haviland,Vivek Misra,Jennifer Titley,Søren M. Bentzen,Paul D.P. Pharoah,Neil G. Burnet,Alison M. Dunning,Catharine M L West +36 more
TL;DR: This largest GWAS to date provides evidence of true association between common genetic variants and toxicity, and Associations with toxicity appeared to be tumour site-specific.
Journal ArticleDOI
Use of artificial neural networks to predict biological outcomes for patients receiving radical radiotherapy of the prostate
TL;DR: ANNs have been shown to learn something of the complex relationship between treatment parameters and outcome which, if developed further, may prove to be a useful tool in predicting biological outcomes.
Journal ArticleDOI
Microbiota- and Radiotherapy-Induced Gastrointestinal Side-Effects (MARS) Study: A Large Pilot Study of the Microbiome in Acute and Late-Radiation Enteropathy.
Miguel Reis Ferreira,H. Jervoise N. Andreyev,Kabir Mohammed,L. Truelove,L. Truelove,Sharon Gowan,Jia V. Li,Sarah L. Gulliford,Sarah L. Gulliford,Julian R. Marchesi,David P. Dearnaley,David P. Dearnaley +11 more
TL;DR: The microbiota presents opportunities to predict, prevent, or treat radiation enteropathy, with clinical implications for risk assessment, prevention, and treatment of radiation-induced side-effects.